Skip to main content

Advertisement

SpringerLink
Log in

Diagnostic and prognostic power of CSF Tau in amyotrophic lateral sclerosis

  • Original Communication
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

Background

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that still lacks reliable diagnostic biomarkers. This study aims to evaluate the diagnostic and prognostic potential of CSF total Tau (t-Tau), phospho-Tau (p-Tau) and p-Tau/t-Tau ratio in ALS patients using CSF neurofilament light (NFL) as the reference biomarker.

Methods

Eighty-five incident ALS, 30 ALS-mimicking (AM) diseases and 51 other non-neurodegenerative diseases (ONND) were included in the study.

Results

ALS patients had higher levels of CSF t-Tau and lower p-Tau/t-Tau ratio than AM (p = 0.005 and p = 0.006) and ONND (p < 0.001). CSF t-Tau levels discriminated ALS from AM with a sensitivity of 69% and specificity of 60%, and from ONND with a sensitivity of 88% and specificity of 51%. These values were lower than the accuracy of CSF NFL in ALS (sensitivity 86% and specificity 87% in distinguishing ALS from AM and sensitivity 83% and specificity 75% from ONND); CSF t-Tau correlated with progression rate and SNIP. CSF p-Tau did not show relation with any ALS clinical features. CSF NFL significantly correlated with all considered clinical parameters. High levels of CSF t-Tau and NFL were related to poor survival.

Conclusion

CSF t-Tau showed no reliable diagnostic significance but the relation between the high levels of CSF t-Tau and short survival suggests the potential prognostic role of this biomarker in ALS. However, CSF NFL was confirmed to be the most reliable and efficient tool for diagnosis and prediction of clinical progression and survival in ALS patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Strong M, Rosenfeld J (2003) Amyotrophic lateral sclerosis: a review of current concepts. Amyotroph Lateral Scler Other Motor Neuron Disord 4(3):136–143

    Article  Google Scholar 

  2. Chiò A, Logroscino G, Traynor BJ et al (2013) Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 41(2):118–130

    Article  Google Scholar 

  3. Chia R, Chiò A, Traynor BJ (2018) Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol 17(1):94–102

    Article  CAS  Google Scholar 

  4. Van den Berg-Vos RM, Visser J, Franssen H et al (2003) Sporadic lower motor neuron disease with adult onset: classification of subtypes. Brain 126(Pt 5):1036–1047

    Article  Google Scholar 

  5. Chiò A, Calvo A, Moglia C, Mazzini L, Mora G, PARALS study group (2011) Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry 82(7):740–746

    Article  Google Scholar 

  6. Turner MR, Kiernan MC, Leigh PN, Talbot K (2009) Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol 8(1):94–109

    Article  CAS  Google Scholar 

  7. Bowser R, Turner MR, Shefner J (2011) Biomarkers in amyotrophic lateral sclerosis: opportunities and limitations. Nat Rev Neurol 7(11):631–638

    Article  CAS  Google Scholar 

  8. Tarasiuk J, Kułakowska A, Drozdowski W, Kornhuber J, Lewczuk P (2012) CSF markers in amyotrophic lateral sclerosis. J Neural Transm 119(7):747–757

    Article  CAS  Google Scholar 

  9. Tortelli R, Ruggieri M, Cortese R et al (2012) Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression. Eur J Neurol 19(12):1561–1567

    Article  CAS  Google Scholar 

  10. Tortelli R, Copetti M, Ruggieri M et al (2015) Cerebrospinal fluid neurofilament light chain levels: marker of progression to generalized amyotrophic lateral sclerosis. Eur J Neurol 22(1):215–218

    Article  CAS  Google Scholar 

  11. Steinacker P, Feneberg E, Weishaupt J et al (2016) Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry 87(1):12–20

    PubMed  Google Scholar 

  12. Poesen K, De Schaepdryver M, Stubendorff B et al (2017) Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology 88(24):2302–2309

    Article  CAS  Google Scholar 

  13. Süssmuth SD, Tumani H, Ecker D, Ludolph AC (2003) Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum. Neurosci Lett 353(1):57–60

    Article  Google Scholar 

  14. Jiménez-Jiménez FJ, Hernánz A, Medina-Acebrón S et al (2005) Tau protein concentrations in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neurol Scand 111(2):114–117

    Article  Google Scholar 

  15. Brettschneider J, Petzold A, Süssmuth SD, Ludolph AC, Tumani H (2006) Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology 66(6):852–856

    Article  CAS  Google Scholar 

  16. Paladino P, Valentino F, Piccoli T, Piccoli F, La Bella V (2009) Cerebrospinal fluid tau protein is not a biological marker in amyotrophic lateral sclerosis. Eur J Neurol 16(2):257–261

    Article  CAS  Google Scholar 

  17. Goedert M (1993) Tau protein and the neurofibrillary pathology of Alzheimer’s disease. Trends Neurosci 16:460–465

    Article  CAS  Google Scholar 

  18. Süssmuth SD, Reiber H, Tumani H (2001) Tau protein in cerebrospinal fluid (CSF): a blood-CSF barrier related evaluation in patients with various neurological diseases. Neurosci Lett 300(2):95–98

    Article  Google Scholar 

  19. Sunderland T, Linker G, Mirza N et al (2003) Decreased beta amyloid1–42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 289:2094–2103

    Article  Google Scholar 

  20. Satoh K, Shirabe S, Tsujino A et al (2007) Total tau protein in cerebrospinal fluid and diffusion-weighted MRI as an early diagnostic marker for Creutzfeldt–Jakob disease. Dement Geriatr Cogn Disord 24:207–212

    Article  CAS  Google Scholar 

  21. Grossman M, Elman L, McCluskey L et al (2014) Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis. JAMA Neurol 2014;71(4):442–448

    Article  Google Scholar 

  22. Wilke C, Deuschle C, Rattay TW, Maetzler W, Synofzik M (2015) Total tau is increased, but phosphorylated tau not decreased, in cerebrospinal fluid in amyotrophic lateral sclerosis. Neurobiol Aging 36(2):1072–1074

    Article  CAS  Google Scholar 

  23. Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1(5):293–299

    Article  CAS  Google Scholar 

  24. Strong MJ, Abrahams S, Goldstein LH et al (2017) Amyotrophic lateral sclerosis-frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener 18(3–4):153–174

    Article  Google Scholar 

  25. Cedarbaum JM, Stambler N, Malta E et al (1999) The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 169(1–2):13–21

    Article  CAS  Google Scholar 

  26. Aitkens S, Lord J, Bernauer E et al (1989) Relationship of manual muscle testing to objective strength measurements. Muscle Nerve 12:173–177

    Article  CAS  Google Scholar 

  27. Tortelli R, Copetti M, Panza F et al (2016) Time to generalisation as a predictor of prognosis in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 87(6):678–679

    Article  Google Scholar 

  28. Kimura F, Fujimura C, Ishida S et al (2006) Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology 66:265–267

    Article  CAS  Google Scholar 

  29. Miller JM, Moxham J, Green M (1985) The maximal sniff in the assessment of diaphragm function in man. Clin Sci 69:91–96

    Article  CAS  Google Scholar 

  30. Woolley SC, York MK, Moore DH et al (2010) Detecting frontotemporal dysfunction in ALS: utility of the ALS cognitive behavioral screen (ALS-CBS). Amyotroph Lateral Scler 11(3):303–311

    Article  Google Scholar 

  31. Poletti B, Solca F, Carelli L et al (2016) The validation of the Italian Edinburgh cognitive and behavioural ALS screen (ECAS). Amyotroph Lateral Scler Frontotemporal Degener 17(7–8):489–498

    Article  Google Scholar 

  32. Goldstein ME, Sternberger NH, Sternberger LA (1987) Phosphorylation protects neurofilaments against proteolysis. J Neuroimmunol 14(2):149–160

    Article  CAS  Google Scholar 

  33. Pijnenburg YA, Verwey NA, van der Flier WM, Scheltens P, Teunissen CE (2015) Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes. Alzheimer’s Dement 1(4):505–512

    Google Scholar 

  34. Petzold A, Altintas A, Andreoni L et al (2010) Neurofilament ELISA validation. J Immunol Methods 352(1–2):23–31

    Article  CAS  Google Scholar 

  35. Bourbouli M, Rentzos M, Bougea A et al (2017) Cerebrospinal fluid TAR DNA-binding protein 43 combined with Tau proteins as a candidate biomarker for amyotrophic lateral sclerosis and frontotemporal dementia spectrum disorders. Dement Geriatr Cogn Disord 44(3–4):144–152

    Article  CAS  Google Scholar 

  36. Ganesalingam J, An J, Shaw CE et al (2011) Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS. J Neurochem 117(3):528–537

    Article  CAS  Google Scholar 

  37. Lehnert S, Costa J, de Carvalho M et al (2014) Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 15(5–6):344–350

    Article  Google Scholar 

  38. Labra J, Menon P, Byth K et al (2016) Rate of disease progression: a prognostic biomarker in ALS. J Neurol Neurosurg Psychiatry 87(6):628–632

    Article  Google Scholar 

  39. Chiò A, Logroscino G, Hardiman O et al (2009) Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler 10(5–6):310–323

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurology Unit, Department of Basic Medical Sciences, Neurosciences and Sense Organs (DBMSNSO), University of Bari “Aldo Moro”, Piazza Giulio Cesare 11, 70100, Bari, Italy

    Antonio Scarafino, Eustachio D’Errico, Alessandro Introna, Angela Fraddosio, Eugenio Distaso, Irene Tempesta, Antonella Morea, Antonella Mastronardi & Isabella Laura Simone

  2. Neurophysiopathology Unit, Department of Basic Medical Sciences, Neurosciences and Sense Organs (DBMSNSO), University of Bari “Aldo Moro”, Piazza Giulio Cesare 11, 70100, Bari, Italy

    Rosaria Leante, Maddalena Ruggieri & Mariangela Mastrapasqua

Authors
  1. Antonio Scarafino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eustachio D’Errico
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alessandro Introna
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Angela Fraddosio
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eugenio Distaso
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Irene Tempesta
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Antonella Morea
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Antonella Mastronardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Rosaria Leante
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Maddalena Ruggieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Mariangela Mastrapasqua
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Isabella Laura Simone
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Isabella Laura Simone.

Ethics declarations

Conflicts of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Scarafino, A., D’Errico, E., Introna, A. et al. Diagnostic and prognostic power of CSF Tau in amyotrophic lateral sclerosis. J Neurol 265, 2353–2362 (2018). https://doi.org/10.1007/s00415-018-9008-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-018-9008-3

Keywords

Search

Navigation